Vaccine Response Impaired
33
4
5
21
Key Insights
Highlights
Success Rate
95% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
3.0%
1 terminated out of 33 trials
95.5%
+8.9% vs benchmark
27%
9 trials in Phase 3/4
14%
3 of 21 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 21 completed trials
Clinical Trials (33)
RSV Vaccine in Transplant Recipients
Safety and Immunogenicity of Recombinant Zoster Vaccine for Transplant Recipients
Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?
Antibiotics and Vaccine Immune Responses Study
Iron and COVID-19 Vaccine Response
Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
Impact of Metformin on Immunity
Vaccine Observation to Include All Communities for Equitable Science
COVID19 Vaccine in SOT Adult Recipients
COVID-19 Vaccine Efficacy in Patients With Malignant Pathologies
Efficacy and Safety of the Anti- COVID-19 Vaccin in Clinical Hematology Patients
Heplisav-B Revaccination for Hepatitis B Vaccine Nonresponders
Immune Response to SARS-CoV-2/COVID-19 Vaccination in Sarcoidosis
Effectiveness of Booster With 1 or 2 Doses of HAV Vaccine Among HIV-infected Patients
Pregnancy, Arsenic and Immune Response
Immune-Related Trafficking and Signaling in Human Skin Associated With Low-Power, Infrared Laser Treatment
Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients
Immune Response to the COVID-19 Vaccine
RECOVAC Repeated Vaccination Study
Immune Response to Third Dose of COVID-19 Vaccine in Solid Organ Transplant